Business
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026Five additional Phase 3 azetukalner studies continuing to enroll patients in multiple indications in epilepsy and neuropsychiatry; Phase 3 X-NOVA2 topline data in MDD expected in H1 2027 Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain VANCOUVER, British Columbia and BOSTON
About this update from Xenon Pharmaceuticals Inc.
[{"type":"image","alt":"Xenon Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Xenon Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/512e4110e9e95e88ef2c02e7ad2efa3b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2itbMrMqQmDxiBhD2XGQ.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/512e4110e9e95e88ef2c02e7ad2efa3b","width":250,"height":80}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026","length":126,"tagName":"p"}]},{"val":[{"type":"text","content":"Five additional Phase 3 azetukalner studies continuing to enroll patients in multiple indications in epilepsy and neuropsychiatry; Phase 3 X-NOVA2 topline data in MDD expected in H1 2027 ","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain ","length":153,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":465,"olType":false},{"type":"text","content":"VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today outlined forward momentum across the Company’s Phase 3 portfolio and discussed pipeline progress at the 2026 J.P. Morgan Healthcare Conference.","length":439,"tagName":"p"},{"type":"text","content":"“We’re approaching an important inflection point as we expect to report topline data for our X-TOLE2 Phase 3 study of azetukalner in focal onset seizures later this quarter, a major milestone on the path toward regulatory submission, and ultimately, approval and our first commercial launch,” said Ian Mortimer, President and Chief Executive Officer of Xenon. “We are excited about the anticipation in the epilepsy community and our potential opportunity to bring a different mechanism to the epilepsy treatment paradigm. Beyond our Phase 3 X-TOLE2 program, we continue to build ...